• Viking Therapeutics Inc VKTX.OQ reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -25 cents. The mean expectation of fifteen analysts for the quarter was for a loss of 28 cents per share. Wall Street expected results to range from -34 cents to -22 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Viking Therapeutics Inc's reported EPS for the quarter was a loss of 32 cents​.

• The company reported a quarterly loss of $35.42 million.

• Viking Therapeutics Inc shares had fallen by 19.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Viking Therapeutics Inc is $110.00

This summary was machine generated from LSEG data February 5 at 10:45 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)